Monday, 8 November 2010

BG-12 shows promise in relapsing remitting MS

From the MS Trust:
BG-12 is an experimental new drug treatment for people with relapsing remitting multiple sclerosis (MS) that is taken orally (by mouth). The mechanism of action is not fully understood, but preclinical studies have suggested that BG-12 may have complex neuroprotective and anti-inflammatory effects.  Read more here.